Literature DB >> 9645692

The endothelin subtype A receptor undergoes agonist- and antagonist-mediated internalization in the absence of signaling.

N Bhowmick1, P Narayan, D Puett.   

Abstract

The potent vasoconstrictor and mitogen to smooth muscle cells, endothelin-1 (ET-1), acts via two distinct G protein-coupled receptors, subtype A (ETAR) and subtype B, that are coupled primarily to the Gq-phospholipase C signaling pathway. It is known that ET-1 binding to ETAR promotes internalization, with subsequent degradation of at least a portion of the bound ligand. To investigate whether signaling is required for endocytosis, we developed stably transfected lines of human embryonic kidney 293 cells expressing wild-type ETAR and a receptor chimera (ETARC) in which the C-terminal cytoplasmic tail to ETAR was replaced with that of the lutropin receptor, another G protein-coupled receptor, but one which signals through the Gs-adenylyl cyclase pathway. ETARC binds ET-1 like ETAR, but is deficient in signaling. Using a combined concanavalin A/sucrose gradient centrifugation technique to separate plasma membranes from other cellular membranes, we found that [125I]ET-1 is rapidly internalized into ETAR-expressing cells at 37 C (t1/2 for internalization = 5 min; endocytic rate constant = 0.1 min(-1); ETARC-expressing cells also internalize [125I]ET-1, albeit at a somewhat slower rate than wild-type receptor (t1/2 for internalization = 15 min; endocytic rate constant = 0.03 min(-1). Using immunofluorescence confocal microscopy and an antibody developed to the N-terminal region of ETAR, qualitatively similar results were obtained. In addition, it was found using confocal microscopy that the ETAR-selective antagonist, BQ123, also promoted rapid internalization in cells expressing ETAR. These results establish that inositol 1,4,5-trisphosphate signaling is not required for ligand-mediated internalization of ETAR and suggest that a receptor conformational change is necessary. Moreover, the finding that BQ123 promotes ETAR internalization is novel and has potentially important implications in its clinical use.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9645692     DOI: 10.1210/endo.139.7.6105

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  14 in total

1.  Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.

Authors:  Anke-Katrin Volz; Andreas Krause; Walter Emil Haefeli; Jasper Dingemanse; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

Review 2.  Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma.

Authors:  Raymond B Penn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-02-16       Impact factor: 3.000

3.  Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.

Authors:  Mihaela Ginj; Hanwen Zhang; Beatrice Waser; Renzo Cescato; Damian Wild; Xuejuan Wang; Judit Erchegyi; Jean Rivier; Helmut R Mäcke; Jean Claude Reubi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-20       Impact factor: 11.205

4.  Ubiquitination-deubiquitination balance dictates ligand-stimulated PTHR sorting.

Authors:  Verónica Alonso; Clara E Magyar; Bin Wang; Alessandro Bisello; Peter A Friedman
Journal:  J Bone Miner Res       Date:  2011-12       Impact factor: 6.741

5.  Ral and phospholipase D2-dependent pathway for constitutive metabotropic glutamate receptor endocytosis.

Authors:  Moshmi Bhattacharya; Andy V Babwah; Christina Godin; Pieter H Anborgh; Lianne B Dale; Michael O Poulter; Stephen S G Ferguson
Journal:  J Neurosci       Date:  2004-10-06       Impact factor: 6.167

6.  Endothelin receptor dimers evaluated by FRET, ligand binding, and calcium mobilization.

Authors:  Nathan J Evans; Jeffery W Walker
Journal:  Biophys J       Date:  2008-04-18       Impact factor: 4.033

7.  Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors.

Authors:  Mounia Azzi; Pascale G Charest; Stéphane Angers; Guy Rousseau; Trudy Kohout; Michel Bouvier; Graciela Piñeyro
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-17       Impact factor: 11.205

8.  Mu-opioid receptor redistribution in the locus coeruleus upon precipitation of withdrawal in opiate-dependent rats.

Authors:  Jillian L Scavone; Elisabeth J Van Bockstaele
Journal:  Anat Rec (Hoboken)       Date:  2009-03       Impact factor: 2.064

9.  Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists.

Authors:  Anke-Katrin Volz; Jasper Dingemanse; Andreas Krause; Thorsten Lehr
Journal:  Pharm Res       Date:  2019-12-10       Impact factor: 4.200

Review 10.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.